AIM Total Utang marang Modal AIM ImmunoTech Inc.

AIM (AIM ImmunoTech) - tandha merek perusahaan

This chart of current AIM (AIM) quotes demonstrates a total debt-to-equity ratio of 0.50. The firm's financial stability is declining due to the slow market rollout of Ampligen, which undermines profitability despite existing patents. Pipeline risks are being minimized through the adaptation of immunomodulators to combat oncology and viruses. High product quality is guaranteed by the implementation of automated interferon synthesis systems.

AIM Rasio Kabeh Utang marang Dana Pribadi AIM ImmunoTech Inc. (04.07.2022 - 28.10.2026)

Rincian analitis perusahaan AIM ImmunoTech

- rega lan prakiraan konsensus rega:
Rega saham AIM ImmunoTech|AIM - Konsensus nilai wajar
- data kapitalisasi pasar:
Kapitalisasi pasar AIM ImmunoTech|AIM - Nilai Perusahaan
- data kapitalisasi buku:
Aset Bersih saben Siji Saham AIM ImmunoTech|AIM - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku aimimmuno.com|AIM - Gunggung Aset Perusahaan
- data utang lan likuiditas:
Total Utang marang Modal AIM ImmunoTech|AIM - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas AIM ImmunoTech Inc.|AIM - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku AIM ImmunoTech
Analisis dhasar perusahaan:AIM ImmunoTech - AIM
Produk dadi AIM ImmunoTech, Inc.

This metric measures the proportion of borrowed funds within the balance sheet structure, determining the business's level of dependence on external financing and its vulnerability to credit shocks. The diversification of Ampligen clinical trials reduces operational risks for AIM ImmunoTech (AIM), meaning an analysis of the debt-to-equity ratio allows investors to assess the company's financial stability while executing its long-term strategy for immunomodulator development.

Pesaing wigati

ARGX - Total Utang marang Modal|Rasio Kabeh Utang marang Dana Pribadi BioNTech Inc.|Total Utang marang Modal ABVX|Total Utang marang Modal ADMA (ADMA Corp)|Utang marang Ekuitas Protagonist Therapeutics|immunovant.com - Rasio Kabeh Utang marang Dana Pribadi|KNSA: Utang marang Ekuitas|GRFS - Rasio Total Utang marang Ekuitas|ADPT: Total Utang marang Modal|Total Utang marang Modal Celldex Corp|AUPH - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi biocryst.com|VERA (Vera Therapeutics) - Total Utang marang Modal|Koefisien Total Utang marang Modal DNTH (Dianthus Therapeutics Inc)|Pharvaris Corp - Utang marang Ekuitas|AbCellera - Rasio Total Utang marang Ekuitas|TRML: Utang marang Ekuitas|precigen.com (PGEN) - Rasio Total Utang marang Ekuitas|PHAR: Rasio Total Utang marang Ekuitas|NKTR (Nektar Therapeutics Inc) - Total Utang marang Modal|Utang marang Ekuitas Upstream Bio Corp (UPB)|Rasio Utang marang Ekuitas Zenas Corp|Immunome, Inc. - Total Utang marang Modal|Utang marang Modal gossamerbio.com (GOSS)|Total Utang marang Modal KALV (KalVista Pharmaceuticals, Inc.)|Total Utang marang Modal Septerna, Inc. SEPN|Total Utang marang Modal PVLA (Pieris Pharmaceuticals Inc)|SVRA: Koefisien Total Utang marang Modal|RIGL (Rigel Pharmaceuticals) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas anaptysbio.com|ATXS - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi enGene Holdings Inc|RAPT (RAPT Therapeutics, Inc.) - Total Utang marang Modal|Koefisien Total Utang marang Modal JBIO (aerovatetx.com)|Aclaris Therapeutics - Utang marang Ekuitas|kyvernatx.com - Rasio Total Utang marang Ekuitas|TLSA: Utang marang Ekuitas|Cabaletta Bio Inc. (CABA) - Rasio Total Utang marang Ekuitas|VTYX: Rasio Total Utang marang Ekuitas|THTX (Theratechnologies, Inc) - Total Utang marang Modal|Utang marang Ekuitas Avalo Therapeutics, Inc (AVTX)|Rasio Utang marang Ekuitas ELDN|Agenus Inc. - Utang marang Ekuitas|Utang marang Modal Climb Bio Inc. CLYM|Rasio Total Utang marang Ekuitas Zura Bio Limited (ZURA)|Utang Agregat marang Modal aTyr Pharmaceuticals ATYR|ADAG (Adagene Corp) - Total Utang marang Modal|IMA - Utang marang Modal|STTK (shattucklabs.com) - Total Utang marang Modal|Equillium (EQ) - Rasio Total Utang marang Ekuitas|CNTB - Total Utang marang Modal|Rasio Kabeh Utang marang Dana Pribadi Immunic Inc|Total Utang marang Modal ATRA|Total Utang marang Modal inflarx.de (IFRX)|Total Utang marang Modal XFOR|Adicet Bio Inc. - Koefisien Total Utang marang Modal|CELU: Utang marang Ekuitas|INMB: Rasio Total Utang marang Ekuitas|Utang marang Ekuitas Barinthus Biotherapeutics (BRNS)|kezarlifesciences.com (KZR) - Utang Agregat marang Ekuitas|SABS - Total Utang marang Modal|Rasio Kabeh Utang marang Dana Pribadi Akari Therapeutics PLC|Total Utang marang Modal ENLV|Total Utang marang Modal QTTB (q32bio.com)|Utang marang Ekuitas GeoVax Labs, Inc.|edesabiotech.com - Rasio Kabeh Utang marang Dana Pribadi|IBIO: Utang marang Ekuitas|CARM - Rasio Total Utang marang Ekuitas|XTLB: Total Utang marang Modal|Total Utang marang Modal Bolt Biotherapeutics, Inc.|HCWB - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi Aptevo|ADTX (Aditxt) - Total Utang marang Modal|Koefisien Total Utang marang Modal GRI (GRI Bio Inc)|XORTX - Utang marang Ekuitas|Vyome Therapeutics - Rasio Total Utang marang Ekuitas|REVB: Utang marang Ekuitas|indaptusrx.com (INDP) - Rasio Total Utang marang Ekuitas|SCNI: Rasio Total Utang marang Ekuitas|CALI (CalciMedica) - Total Utang marang Modal|Utang marang Ekuitas Affimed NV (AFMD)|Rasio Utang marang Ekuitas Allakos Therapeutics|HOOKIPA Pharma Inc. - Total Utang marang Modal|Utang marang Modal igmbio.com (IGMS)|Total Utang marang Modal ITOS (iTeos Therapeutics, Inc.)|Total Utang marang Modal Ocean Biomedical Inc OCEA|Total Utang marang Modal TCBP (TC BioPharm (Holdings) PLC)|THRD: Koefisien Total Utang marang Modal